Epistemis

Rotigotine

  • Transdermal Non-Ergotic Dopamine Agonist / Continuous Modulator

Non-ergot agonist agent administered via a continuous transdermal patch, designed to simulate physiological dopaminergic stimulation.

Mechanism

Chemical and Commercial Profile

Common trade names: Neupro.
Group: Antiparkinsonian, non-ergotic synthetic dopamine agonist for transdermal use.

Mechanism of Action

Rotigotine acts by **continuous stimulation of the striatal dopamine receptors D1, D2, D3 and D4**, as well as the serotonergic 5-HT1A and α2B adrenergic receptors. Administration by continuous transdermal patch simulates constant dopaminergic stimulation in the CNS, avoiding peaks and valleys in plasma concentration of oral drugs and reducing the development of motor fluctuations.

Pharmacokinetics

Pharmacokinetics

  • Absorption: Continuous through the skin after application of the transdermal patch; Bioavailability is constant with a release rate of ~0.2 mg of drug per cm2 per day. The state of plasma equilibrium is reached 24 hours after the first application.
  • Distribution: Very high binding to plasma proteins (92%). Distribution volume of 8.4 L/kg. It easily crosses the blood-brain barrier.
  • Metabolism: Extensive hepatic via conjugation with glucuronic acid (70%) and hydroxylation catalyzed by multiple cytochrome isoenzymes (CYP2C19, CYP3A4, CYP2D6). Produces inactive metabolites.
  • Excretion: Renal (70%) and fecal (30%) mainly in the form of inactive conjugated metabolites.
  • Half-life (t1/2): Apparent plasma 5-7 hours after patch removal; The biological therapeutic effect is constant as long as it remains applied.

Indicators and dose

Indications

  • Initial monotherapy of early phase Idiopathic Parkinson's Disease, to delay the need for oral levodopa.
  • Treatment of advanced Parkinson's Disease in combination with levodopa, to reduce motor fluctuations ("wearing-off").
  • Symptomatic treatment of moderate to severe Restless Legs Syndrome (RLS).

Dosage and Settings

  • Initial Monotherapy (Parkinson's Disease): Apply a 2 mg patch/24 hours; increase by 2 mg/24 hours each week to a common clinical range of 6-8 mg/24 hours (maximum of 8 mg/24 hours).
  • Adjuvant Therapy (Advanced Parkinson's): Start with a 4 mg/24-hour patch; progressive titration to a common maximum of 16 mg/24 hours.
  • Restless Legs Syndrome: Start with 1 mg/24 hours, limit 3 mg/24 hours.
  • Renal/Hepatic Failure: No adjustments required in moderate to severe renal failure, nor in compensated Child-Pugh A or B cirrhosis. Caution in Child-Pugh C.

Security

Contraindications

  • Hypersensitivity to the active ingredient or excipients of the patch.
  • Submission to **Magnetic Resonance (MRI)** procedures or electrical cardioversion (the patch contains aluminum in its back layer and can cause severe skin burns due to overheating).

Adverse Effects (ADR)

Local Skin Reactions due to Rotigotine

The most common adverse effect of rotigotine is the development of local reactions at the application site of the patch, affecting 30-40% of patients. It presents with mild erythema, intense pruritus, contact dermatitis, and local vesiculation. It is controlled by a systematic daily rotation of the application areas (arms, shoulders, thighs, abdomen), not repeating the same application site within a minimum period of 14 days.

  • CNS: Sudden sleep attacks, visual hallucinations, headache, sleep insomnia, dizziness, nightmares, impulse control disorder (compulsive gambling, hypersexuality).
  • Gastrointestinal: Temporary nausea, vomiting, gastroesophageal reflux.
  • General: Persistent orthostatic hypotension, moderate peripheral edema, weight gain (moderate).

Clinical Interactions

  • Dopaminergic Antagonists: Neuroleptics or metoclopramide competitively block striatal receptors, nullifying the clinical efficacy of rotigotine.
  • CNS depressants: Pharmacodynamic synergy that multiplies the sedative effects with benzodiazepines, alcohol and opioids.

Pregnancy and Breastfeeding

FDA Category: C. Very limited human data; associates decreased embryonic growth in animals. Breastfeeding: Absolutely contraindicated. Like other dopaminergic drugs, it potently inhibits pituitary prolactin release reflexively, suppressing lactation, in addition to being excreted in breast milk.

Epistemis is educational review material. It is not a medical device, does not diagnose or prescribe treatment, and does not replace formal medical training, current clinical guidelines, or professional clinical judgment.

PreviousRopinirole
System
Antiepileptics and Antiparkinsonians
Cluster
Transdermal Non-Ergotic Dopamine Agonist / Continuous…
Download Epistemis